Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
2023 · Nature Medicine · 385 citations
https://doi.org/10.1038/s41591-023-02453-x
B
Bertrand Routy
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
115
Papers
7.0K
Citations
35
h-index
56
i10-index
Bertrand Routy is an academic researcher from Centre Hospitalier de l’Université de Montréal. The author has contributed to research in topics: Gut microbiota and health & Cancer Immunotherapy and Biomarkers & Clostridium difficile and Clostridium perfringens research. The author has an h-index of 35, co-authored 98 publications.
ORCID: 0000-0003-1955-9149Papers by this author
worksMEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells
2022 · Cancer Cell · 199 citations
https://doi.org/10.1016/j.ccell.2021.12.009
A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers
2023 · Science · 195 citations
https://doi.org/10.1126/science.abo2296
Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome
2024 · Cell · 142 citations
https://doi.org/10.1016/j.cell.2024.05.029
Melanoma and microbiota: Current understanding and future directions
2023 · Cancer Cell · 69 citations
https://doi.org/10.1016/j.ccell.2023.12.003
Ileal immune tonus is a prognosis marker of proximal colon cancer in mice and patients
2020 · Cell Death and Differentiation · 23 citations
https://doi.org/10.1038/s41418-020-00684-w
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat